Braveheart Bio (BRVE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$2.51
- Estimate
- $2.69
- Surprise
- -193.4%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Braveheart Bio (BRVE) reported a wider loss than forecast — adjusted EPS of -$2.51 against the $2.69 estimate (a 193.4% shortfall).
Coverage in the report window
- Braveheart Bio Q2 EPS $(2.51) — benzinga, 2026-09-08
Where TrendMatrix's rating stands now
TrendMatrix currently rates BRVE Sell at 5.5/10; no pre/post engine snapshot brackets this report.
0 of the last 1 quarters beat the estimate; this quarter's -193.4% surprise compares with a -193.4% four-quarter average. Next scheduled report: 2027-03-18.
What argues against it
- Quality below floor (2.5 < 4.0)
- Momentum score 4.0/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.62
- Price target
- $38.67
- Stop
- $18.25
- Upside to target
- +97.1%
- Reward-to-risk
- 6.5:1
Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.
BRVE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.76B
- P/E (fwd)
- -9.9
- 52-week range
- $16.70–$32.00
- Off 52-week high
- 38.7%
- RSI (14)
- 39
- Volume vs avg
- 1.32×
- Score today
- 5.5/10